T therapies is an expensive business. The fundamental problem is that CAR-T production is not a good fit for centralized manufacturing.

pCenter for Innovative Care in Aging, Johns Hopkins University, Baltimore, MA, USA qDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MA, USA rDepartment of ...